A recent systematic review and meta-analysis evaluated the effectiveness of tuberculosis preventive treatment (TPT) in patients with rheumatic diseases.

The study found that TPT, particularly isoniazid monotherapy, reduced tuberculosis risk by 24% overall and 46% in high TB burden regions. Screening strategies also influenced TPT efficacy, and patients with rheumatic diseases experienced varying levels of risk reduction. The investigators recommended extending isoniazid treatment duration in high TB burden regions and conducting more randomized controlled trials to refine preventive strategies.

Source: eClinicalMedicine